stars 1 stars 2 stars 3

CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which all of our China operations are conducted. CASI is dedicated to the development and delivery of high-quality pharmaceutical products and innovative therapeutics to patients worldwide while targeting the China market. We are focused on acquiring, licensing, developing and commercializing products that address areas of unmet medical need. We intend to become the leading platform to launch medicines in the greater China market leveraging our China-based regulatory and commercial competencies and our global drug development expertise. We have a strong and growing product pipeline of commercially available and clinical stage drug candidates, and will continue to (i) acquire additional approved and clinical stage drug candidates through in-license and acquisitions, and (ii) explore drug candidates in preclinical development. CASI’s product portfolio includes (i) an autologous anti-CD19 T-cell therapy investigative product (CNCT19) being developed for the treatment of B-ALL and NHL (ii) CID-103, an anti-CD38 monoclonal antibody being developed for the treatment of certain hematological malignancies; (iii) China regional rights to three U.S. Food and Drug Administration (FDA)-approved drugs (EVOMELA® (melphalan hydrochloride for injection) approved by China’s National Medical Products Administration (NMPA) for marketing in China, ZEVALIN® (ibritumomab tiuxetan) and MARQIBO® (vincristine sulfate LIPOSOME injection) approved by NMPA for registration confirmatory trials in China; and (iv) a portfolio of FDA-approved abbreviated new drug applications (ANDAs).

View Top Employees from CASI Pharmaceuticals, Inc.
Website http://casipharmaceuticals.com
Ticker CASI
Revenue $42 million
Funding $107.8 million
Employees 44 (44 on RocketReach)
Founded 1991
Phone (240) 864-2600
Fax (301) 315-2437
Technologies
HTML, Google Analytics, Font Awesome +11 more (view full list)
Category Pharmaceutical Manufacturing, Chemicals, Petrochemicals, Glass & Gases, Biotechnology, Manufacturing, Science and Engineering, Health Care, Medical, Pharmaceutical
Competitors Aurinia Pharmaceuticals Inc., Bio-Thera Solutions, CrystalGenomics, Inc., Heron Therapeutics, Inc., Otonomy, Inc
SIC SIC Code 28 Companies, SIC Code 283 Companies
NAICS NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 325414 Companies, NAICS Code 54171 Companies, 541711, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies

CASI Pharmaceuticals, Inc. Questions

The CASI Pharmaceuticals, Inc. annual revenue was $42 million in 2024.

Wei-Wu He is the Chairman of CASI Pharmaceuticals, Inc..

44 people are employed at CASI Pharmaceuticals, Inc..

CASI Pharmaceuticals, Inc. is based in Rockville, Maryland.

The NAICS codes for CASI Pharmaceuticals, Inc. are [54, 325, 325414, 54171, 541711, 32541, 3254, 32, 541, 5417].

The SIC codes for CASI Pharmaceuticals, Inc. are [28, 283].

Top CASI Pharmaceuticals, Inc. Employees

View Similar People
How It Works
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups / month.
Search
Search over 700 million verified professionals across 35 million companies.
Get Contact Info
Get contact details including emails and phone numbers (business & personal).
High Performer Summer 2022 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2 RocketReach is a leader in Lead Intelligence on G2
talentculture2022
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users